EyePoint’s DURAVYU Misses Primary Endpoint in Phase III Wet AMD Trial
MarketBeat
Eyepoint Pharmaceuticals (NASDAQ:EYPT) reported topline results from LUGANO, the first of two Phase III trials evaluating DURAVYU, a vorolanib intravitreal insert, in patients with wet age-related macular degeneration, or wet AMD. The study did not meet its primary non-inferiority endpoint in the fu
NASDAQ:EYPT